EHA evaluation of the ESMO—Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies-Reference-Cited by-同舟云学术

EHA evaluation of the ESMO—Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies

Published:2020 Issue:1 Volume:5 Page:e000611
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Kiesewetter Barbara^ORCID,Cherny Nathan I.,Boissel Nicolas,Cerisoli Francesco,Dafni Urania,de Vries Elisabeth G.E.,Ghia Paolo,Gökbuget Nicola,González-Calle Verónica,Huntly Brian,Jäger Ulrich,Latino Nicola Jane,Douillard Jean-Yves,Malcovati Luca,Mateos Mría-Victoria.,Ossenkoppele Gert J.,Porkka Kimmo,Raderer Markus,Ribera Josep-Maria,Scarfò Lydia,Wester Ruth,Zygoura Panagiota,Sonneveld Pieter

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference115 articles.

1. Value frameworks in oncology: comparative analysis and implications to the pharmaceutical industry;Slomiany;Am Health Drug Benefits,2017

2. Comparative assessment of clinical benefit using the ESMO-Magnitude of clinical benefit scale version 1.1 and the ASCO value framework net health benefit score;Cherny;JCO,2019

3. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology magnitude of clinical benefit scale (ESMO-MCBS);Cherny;Ann Oncol,2015

4. ESMO-Magnitude of clinical benefit scale version 1.1;Cherny;Ann Oncol,2017

5. Accountability for Reasonableness;Daniels;BMJ,2000

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ESMO-Magnitude of Clinical Benefit Scale for haematological malignancies (ESMO-MCBS:H) version 1.0;Annals of Oncology;2023-09

2. Evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for adjuvant radiotherapy in breast cancer;ESMO Open;2023-06

3. Can cancer go green? It’s up to us;Frontiers in Oncology;2023-02-22

4. Pre‐approval and post‐approval availability of evidence and clinical benefit of conditionally approved cancer drugs in Europe: A comparison with standard approved cancer drugs;British Journal of Clinical Pharmacology;2022-01-05

5. The wider perspective: twenty years of clinical trials in myelodysplastic syndromes;British Journal of Haematology;2021-10-10